DrugPatentWatch Database Preview
Patent: 10,017,762
» See Plans and Pricing
Summary for Patent: 10,017,762
| Title: | Compositions and methods for treating or preventing lupus |
| Abstract: | The present disclosure provides methods for inhibiting and/or reducing self-reactive IgE and/or basophils, thereby treating or preventing lupus, lupus nephritis, and lupus-related disorders. |
| Inventor(s): | Rivera; Juan (Mechanicsburg, PA), Charles; Nicolas (Asnieres sur Seine, FR) |
| Assignee: | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) |
| Application Number: | 15/498,202 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,017,762
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 001 | 1997-11-26 | Start Trial | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | 2039-02-26 | RX | search | |
| Genentech | RITUXAN | rituximab | SOLUTION;INTRAVENOUS | 103705 | 002 | 1997-11-26 | Start Trial | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | 2039-02-26 | RX | search | |
| Human Genome Sciences Inc. | BENLYSTA | belimumab | INJECTABLE; INJECTION | 125370 | 001 | 2011-03-09 | Start Trial | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | 2039-02-26 | RX | search | |
| Human Genome Sciences Inc. | BENLYSTA | belimumab | INJECTABLE; INJECTION | 125370 | 002 | 2011-03-09 | Start Trial | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | 2039-02-26 | RX | search | |
| Glaxosmithkline Llc | BENLYSTA | belimumab | INJECTABLE;INJECTION | 761043 | 001 | 2017-07-20 | Start Trial | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | 2039-02-26 | RX | search | |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) | 2039-02-26 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 10,017,762
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2010364324 | Start Trial |
| Canada | 2818712 | Start Trial |
| Japan | 2014505020 | Start Trial |
| Japan | 5850943 | Start Trial |
| South Korea | 101813482 | Start Trial |
| South Korea | 20140019303 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
